Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.76 and traded as low as $0.59. Karyopharm Therapeutics shares last traded at $0.62, with a volume of 791,301 shares traded.

Analysts Set New Price Targets

Several research firms have recently commented on KPTI. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Monday, February 10th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. Finally, Piper Sandler boosted their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Up 1.1 %

The company’s 50-day moving average is $0.67 and its two-hundred day moving average is $0.76. The company has a market cap of $77.81 million, a P/E ratio of -0.54 and a beta of 0.06.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Geode Capital Management LLC boosted its stake in Karyopharm Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after purchasing an additional 43,856 shares during the period. GSA Capital Partners LLP boosted its position in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after acquiring an additional 792,283 shares during the period. FMR LLC boosted its position in shares of Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after acquiring an additional 76,510 shares during the period. Exchange Traded Concepts LLC grew its stake in Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after acquiring an additional 56,613 shares in the last quarter. Finally, Focus Partners Wealth bought a new stake in Karyopharm Therapeutics during the 4th quarter worth approximately $31,000. 66.44% of the stock is currently owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).